Market capitalization | $5.93b |
Enterprise Value | $5.71b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1,772.60 |
P/S ratio (TTM) P/S ratio | 1,841.68 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -58.81% |
Revenue (TTM) Revenue | $3.22m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
18 Analysts have issued a Cytokinetics, Incorporated forecast:
18 Analysts have issued a Cytokinetics, Incorporated forecast:
Sep '24 |
+/-
%
|
||
Revenue | 3.22 3.22 |
59%
59%
|
|
Gross Profit | -10 -10 |
337%
337%
|
|
EBITDA | -511 -511 |
5%
5%
|
EBIT (Operating Income) EBIT | -525 -525 |
6%
6%
|
Net Profit | -576 -576 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Robert Blum |
Employees | 423 |
Founded | 1997 |
Website | www.cytokinetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.